Drug Sponsors

Fujifilm to acquire Cellular Dynamics International

Wednesday, April 1, 2015 01:00 PM

Fujifilm, a multinational photography and imaging company headquartered in Tokyo, has entered into a definitive agreement to acquire Cellular Dynamics International (CDI), a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, via an all-cash tender offer to be followed by a second step merger.

More... »

Quest Diagnostics

AcelRx restructures, reduces workforce 36%

Monday, March 30, 2015 02:17 PM

AcelRx Pharmaceuticals, a California-based specialty pharma focused on development and commercialization of innovative therapies for the treatment of acute pain, has restructured its work force as part of a plan to reduce operating costs and focus its financial and development resources on working with the FDA to seek marketing approval for Zalviso, as well as to continue the development of ARX-04.

More... »


Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015 02:52 PM

Sun Pharmaceutical Industries has begun the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world's fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

More... »

Forma Therapeutics, Cancer Research Technology form two virtual companies

Wednesday, March 25, 2015 03:11 PM

Forma Therapeutics, headquartered in Watertown, Mass., and Cancer Research Technology (CRT) have formed two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, drug discovery scientists and a development network.

More... »

Neovacs forms U.S. subsidiary

Wednesday, March 25, 2015 02:55 PM

Neovacs, a Paris-based biotechnology company focused on autoimmune and inflammatory diseases, has established a wholly-owned U.S. subsidiary, Neovacs Inc. Neovacs Inc. is headquartered in Boston and has been incorporated in Delaware.

More... »

Sanofi, Evotec collaborate to reinforce biomedical research in Toulouse

Wednesday, March 25, 2015 02:47 PM

Sanofi has signed a strategic collaboration agreement with Evotec, a drug discovery alliance and development partnership company, for scientific activities at the Sanofi R&D site in Toulouse (Haute-Garonne), France. This strategic collaboration aims to sustain a high level of scientific and technological activities, maintain jobs and attract new talent and projects to the site.

More... »

Biogen Idec becomes Biogen

Monday, March 23, 2015 03:41 PM

Biogen Idec has dropped the Idec from its name, in a new corporate identity and logo it says reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need, while honoring Biogen’s scientific heritage and legacy as a pioneer in the biotechnology industry.

More... »

EUSA Pharma launches as independent pharma business

Monday, March 23, 2015 03:39 PM

EUSA Pharma (EUSA), a newly-established specialty pharmaceutical business with global reach, has officially launched, following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals.

More... »

Janssen acquires XO1

Friday, March 20, 2015 02:13 PM

Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has acquired XO1, a U.K.-based privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. Financial terms of the transaction have not been disclosed.

More... »

Coronado Biosciences, City of Hope form Mustang Therapeutics

Friday, March 20, 2015 02:03 PM

Coronado Biosciences has formed a new company, Mustang Therapeutics, in partnership with California research and treatment center City of Hope. Mustang initially will focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.

More... »

CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs